Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.60 |
| ▸ | MAOB | P27338 | 3/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | SDHA | P31040 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CALML3 | P27482 | 1/20 | 0.60 |
| ▸ | F10 | P00742 | 4/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5862127 | 0.89 | MAOA (0.58) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6530878 | 0.86 | MAOA (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6528613 | 0.86 | MAOA (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6528609 | 0.86 | MAOA (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| Lithium Ion SCHEMBL6531166 | 0.82 | MAOA (0.50) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6530638 | 0.80 | MAOA (0.53) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6530635 | 0.80 | MAOA (0.53) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL14069798 | 0.80 | MAOA (0.48) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5862835 | 0.79 | MAOA (0.48) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6529223 | 0.79 | MAOA (0.46) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012088-B2 | Indolone oxazolidinones and derivatives thereof | PHARMACIA & UPJOHN COMPANY (US) | 2006-03-14 | — | — | US | claimed |
| US-20040176610-A1 | Indolone oxazolidinones and derivatives thereof | PHARMACIA & UPJOHN COMPANY | 2004-09-09 | — | — | US | claimed |
| US-7012088-B2 | Indolone oxazolidinones and derivatives thereof | PHARMACIA & UPJOHN COMPANY (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040176610-A1 | Indolone oxazolidinones and derivatives thereof | PHARMACIA & UPJOHN COMPANY | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176610-A1 | Indolone oxazolidinones and derivatives thereof | OXA1L, IDO1, NDUFS7 | MAOA 635/4885MAOB 670/4885PTGS1 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.